Small extracellular vesicles from surviving cancer cells as multiparametric monitoring tools of measurable residual disease and therapeutic efficiency

Valcz, Gábor; Buzás, Edit I.; Gatenby, Robert A.; Újvári, Beáta; Molnár, Béla

doi:10.1016/j.bbcan.2024.189088

Cited by 2 publications

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

In vivo gene editing and in situ generation of chimeric antigen receptor cells for next-generation cancer immunotherapy

Zhang,

Huang

2024

J Hematol Oncol

View full text Add to dashboard Cite

Chimeric antigen receptor (CAR) cell therapy has achieved groundbreaking success in treating hematological malignancies. However, its application to solid tumors remains challenging due to complex manufacturing processes, limited in vivo persistence, and transient therapeutic effects. In vivo CAR-immune cells induced by gene delivery systems loaded with CAR genes and gene-editing tools have shown efficiency for anti-tumor immunotherapy. In situ programming of autologous immune cells avoids the safety concerns of allogeneic immune cells, and the manufacture of gene delivery systems could be standardized. Therefore, the in vivo editing and in situ generation of CAR-immune cells might potentially overcome the abovementioned limitations of current CAR cell therapy. This review mainly focuses on CAR structures, gene-editing tools, and gene delivery techniques applied in anti-tumor immunotherapy to help design and develop in situ CAR-immune cell therapy. The recent applications of in vivo CAR-immune cell therapy in both hematologic malignancies and solid tumors are investigated. To sum up, the in vivo editing and in situ generation of CAR therapy holds promise for offering a practical, cost-effective, efficient, safe, and widely applicable approach to the next-generation anti-tumor immunotherapy.

show abstract

In vivo gene editing and in situ generation of chimeric antigen receptor cells for next-generation cancer immunotherapy

Zhang,

Huang

2024

J Hematol Oncol

View full text Add to dashboard Cite

show abstract

Spatially Variable Genes

Biradar,

Suresh,

Nanjundeshwara

et al. 2025

Advances in Medical Diagnosis, Treatment, and Care

View full text Add to dashboard Cite

The clinical translation of spatial transcriptomics represents cancer diagnosis and therapy based on the role and heterogeneity of cancer-associated fibroblasts (CAFs) within the tumor microenvironment (TME). Recent developments in spatial transcriptomics have enabled a detailed characterization of the spatial organization and cellular interactions within tumors. The data integration, multi-omics approaches, along with developing standardized protocols is essential for effective clinical translation. The experimental selection regimes and factorial designs reveals novel insights into the biomarkers and prognostic value of CAFs. The incorporation of optogenetics in cancer therapy and advancements in bio-engineered gene circuits, cellular therapeutics and tissue engineering further underscores the potential to refine patient stratification and improve treatment responsiveness. By integrating spatial transcriptomics into clinical workflows, this work aims to advance personalized cancer therapies and cancer biology.

show abstract

Small extracellular vesicles from surviving cancer cells as multiparametric monitoring tools of measurable residual disease and therapeutic efficiency

Cited by 2 publications

References 62 publications

In vivo gene editing and in situ generation of chimeric antigen receptor cells for next-generation cancer immunotherapy

In vivo gene editing and in situ generation of chimeric antigen receptor cells for next-generation cancer immunotherapy

Spatially Variable Genes

Contact Info

Product

Resources

About